AR027748A1 - Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma - Google Patents
Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la mismaInfo
- Publication number
- AR027748A1 AR027748A1 ARP010101516A ARP010101516A AR027748A1 AR 027748 A1 AR027748 A1 AR 027748A1 AR P010101516 A ARP010101516 A AR P010101516A AR P010101516 A ARP010101516 A AR P010101516A AR 027748 A1 AR027748 A1 AR 027748A1
- Authority
- AR
- Argentina
- Prior art keywords
- globules
- small spheres
- stavudine
- spheres
- extrusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Se proporcionan formas de dosificacion prolongada de estavudina que comprenden pequenas esferas o globulos formados por extrusion-formacion de pequenasesferas o globulos y recubiertos con un recubrimiento de sellado. Las pequenas esferas o globulos s e recubren también con un recubrimiento de liberacionmodificada de modo que una cápsula de gelatina rígida que contiene tales pequenas esferas o globulos proporcionará niveles en sangra de estavudina duranteaproximadamente 24 horas. Las pequenas esfe ras o globulos se preparan de una mezcla seca de estavudina, un agente formador de pequenas esferas o globulos, undiluyente adecuado y una cantidad estabilizadora de estearato de magnesio. El estearato de magnesio, en contraste con otros aditivos far macéuticos similares,se encontro que estabiliza a la estavudina contra la degradacion debido a hidrolisis en presencia de la cantidad limitada de agua necesaria para el proceso deextrusion-formacion de pequenas esferas o globulos. También se incluye en el alcance de la presente cápsulas de gelatina rígida que contienen, además de laspequenas esferas o globulos de estavudina, pequenas esferas o globulos similares que contienen otros agentes terapéuticos utilizados para tratar infeccionesretrovira les.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19358800P | 2000-03-30 | 2000-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR027748A1 true AR027748A1 (es) | 2003-04-09 |
Family
ID=22714247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101516A AR027748A1 (es) | 2000-03-30 | 2001-03-29 | Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma |
Country Status (26)
Country | Link |
---|---|
US (1) | US7135465B2 (es) |
EP (1) | EP1267879A2 (es) |
JP (1) | JP2003528905A (es) |
KR (1) | KR20030011805A (es) |
CN (1) | CN1187052C (es) |
AR (1) | AR027748A1 (es) |
AU (1) | AU2001249591A1 (es) |
BG (1) | BG107157A (es) |
BR (1) | BR0109602A (es) |
CA (1) | CA2404687A1 (es) |
CZ (1) | CZ20023003A3 (es) |
EE (1) | EE200200564A (es) |
GE (1) | GEP20043285B (es) |
HU (1) | HUP0302631A2 (es) |
IL (1) | IL151475A0 (es) |
LT (1) | LT5045B (es) |
LV (1) | LV12939B (es) |
MX (1) | MXPA02009534A (es) |
NO (1) | NO20024645L (es) |
NZ (1) | NZ522250A (es) |
PE (1) | PE20011179A1 (es) |
PL (1) | PL366089A1 (es) |
RU (1) | RU2239435C2 (es) |
SK (1) | SK12822002A3 (es) |
WO (1) | WO2001074329A2 (es) |
ZA (1) | ZA200207760B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US20060153908A1 (en) * | 2002-06-27 | 2006-07-13 | Brian Strong | Spherical pellet formulations |
CA2529984C (en) | 2003-06-26 | 2012-09-25 | Isa Odidi | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
CN100548309C (zh) * | 2004-11-24 | 2009-10-14 | 东北制药总厂 | 司他夫定缓释片剂 |
TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
EA013474B1 (ru) * | 2005-06-16 | 2010-04-30 | Форест Лэборэтериз, Инк. | Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина |
AP2008004389A0 (en) * | 2005-08-31 | 2008-04-30 | Cipla Ltd | Pharmaceutical combinations containing lamivudine,stavudine,stavudine and navirapine |
GB0525461D0 (en) | 2005-12-15 | 2006-01-25 | Archimedes Dev Ltd | Pharmaceutical compositions |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
US20190083399A9 (en) * | 2006-04-03 | 2019-03-21 | Isa Odidi | Drug delivery composition |
EP2007360B1 (en) | 2006-04-03 | 2014-11-26 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
CL2008000746A1 (es) | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
CN102319181B (zh) * | 2011-09-08 | 2014-07-16 | 广东大华农动物保健品股份有限公司 | 一种微囊型动物药品的包被工艺 |
US20140271893A1 (en) * | 2013-03-15 | 2014-09-18 | Mcneil-Ppc, Inc. | Coated phenylephrine particles and use thereof in pharmaceutical formulations |
JP2017522321A (ja) * | 2014-07-17 | 2017-08-10 | ダウ グローバル テクノロジーズ エルエルシー | エチルセルロース分散系とフィルム |
CN105511174A (zh) * | 2016-01-05 | 2016-04-20 | 深圳市华星光电技术有限公司 | 液晶显示面板和显示装置 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671963A (en) | 1983-10-28 | 1987-06-09 | Germino Felix J | Stearate treated food products |
US4670270A (en) | 1984-05-07 | 1987-06-02 | Germino Felix J | Stearate treated food products |
US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
US4978655A (en) * | 1986-12-17 | 1990-12-18 | Yale University | Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses |
GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
DE69231499T2 (de) | 1991-12-30 | 2001-05-03 | Fmc Corp., Philadelphia | Zusammensetzung auf der basis von mikrokristalliner zellulose für die herstellung von kugelförmigen teilchen |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
FI101039B (fi) | 1992-10-09 | 1998-04-15 | Eeva Kristoffersson | Menetelmä lääkepellettien valmistamiseksi |
US5869097A (en) | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
GB9403449D0 (en) | 1994-02-23 | 1994-04-13 | Wellcome Found | Therapeutic benzonitriles |
ES2139195T3 (es) | 1994-03-07 | 2000-02-01 | Vertex Pharma | Derivados de sulfonamidas como inhibidores de la aspartil-proteasa. |
CA2212525A1 (en) | 1995-02-23 | 1996-08-29 | Janssen Pharmaceutica N.V. | Use of fused benzothiazoles as neuroprotectants |
US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US5691372A (en) | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
JP2000515115A (ja) | 1995-12-15 | 2000-11-14 | クライオプリザベーション テクノロジーズ シーシー | ウイルス感染及び細菌感染症治療用および臓器冷凍保存用組成物 |
SE9600072D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
US5883252A (en) | 1996-01-26 | 1999-03-16 | Vertex Pharmaceuticals Incorporated | Aspartyl protease inhibitors |
US5766623A (en) | 1996-03-25 | 1998-06-16 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Compactable self-sealing drug delivery agents |
US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US5780055A (en) | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
US5905068A (en) | 1996-09-24 | 1999-05-18 | Abbott Laboratories | Retroviral protease inhibiting compounds |
ES2255103T3 (es) | 1996-10-25 | 2006-06-16 | Shire Laboratories Inc. | Sistema osmotico de administracion de dosis en forma soluble. |
US5962462A (en) | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
US5919776A (en) | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
US6136827A (en) | 1997-07-25 | 2000-10-24 | Merck & Co., Inc. | Cyclic amine modulations of chemokine receptor activity |
AU8699298A (en) | 1997-08-11 | 1999-03-01 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
DE69828635T2 (de) * | 1997-09-19 | 2005-06-16 | Shire Laboratories, Inc. | Feste lösungskügelchen |
US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
US6180634B1 (en) | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
US6013644A (en) | 1997-12-12 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
EP1039899A2 (en) | 1997-12-19 | 2000-10-04 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
JP2002518452A (ja) | 1998-06-24 | 2002-06-25 | エモリ ユニバーシティ | Hivの治療薬物の製造のための他の抗hiv薬と組み合わせた3’−アジド−2’,3’−ジデオキシウリジンの使用 |
NZ514558A (en) | 1999-03-31 | 2004-02-27 | Uaf Technologies And Res Llc | Viral treatment |
US6136835A (en) | 1999-05-17 | 2000-10-24 | The Procter & Gamble Company | Methods of treatment for viral infections |
-
2001
- 2001-03-29 NZ NZ522250A patent/NZ522250A/en unknown
- 2001-03-29 AR ARP010101516A patent/AR027748A1/es unknown
- 2001-03-29 JP JP2001572074A patent/JP2003528905A/ja active Pending
- 2001-03-29 EE EEP200200564A patent/EE200200564A/xx unknown
- 2001-03-29 RU RU2002126540/15A patent/RU2239435C2/ru not_active IP Right Cessation
- 2001-03-29 MX MXPA02009534A patent/MXPA02009534A/es not_active Application Discontinuation
- 2001-03-29 GE GEAP20016630A patent/GEP20043285B/en unknown
- 2001-03-29 KR KR1020027012769A patent/KR20030011805A/ko not_active Application Discontinuation
- 2001-03-29 WO PCT/US2001/010078 patent/WO2001074329A2/en not_active Application Discontinuation
- 2001-03-29 PL PL01366089A patent/PL366089A1/xx not_active Application Discontinuation
- 2001-03-29 IL IL15147501A patent/IL151475A0/xx unknown
- 2001-03-29 CN CNB018074405A patent/CN1187052C/zh not_active Expired - Fee Related
- 2001-03-29 HU HU0302631A patent/HUP0302631A2/hu unknown
- 2001-03-29 EP EP01922832A patent/EP1267879A2/en not_active Withdrawn
- 2001-03-29 AU AU2001249591A patent/AU2001249591A1/en not_active Abandoned
- 2001-03-29 SK SK1282-2002A patent/SK12822002A3/sk unknown
- 2001-03-29 CZ CZ20023003A patent/CZ20023003A3/cs unknown
- 2001-03-29 US US09/821,103 patent/US7135465B2/en not_active Expired - Lifetime
- 2001-03-29 BR BR0109602-8A patent/BR0109602A/pt not_active IP Right Cessation
- 2001-03-29 CA CA002404687A patent/CA2404687A1/en not_active Abandoned
- 2001-03-30 PE PE2001000297A patent/PE20011179A1/es not_active Application Discontinuation
-
2002
- 2002-09-06 LT LT2002099A patent/LT5045B/lt not_active IP Right Cessation
- 2002-09-26 ZA ZA200207760A patent/ZA200207760B/en unknown
- 2002-09-27 NO NO20024645A patent/NO20024645L/no not_active Application Discontinuation
- 2002-09-30 BG BG107157A patent/BG107157A/xx unknown
- 2002-10-25 LV LVP-02-187A patent/LV12939B/en unknown
Also Published As
Publication number | Publication date |
---|---|
LT2002099A (en) | 2003-04-25 |
RU2002126540A (ru) | 2004-03-27 |
EP1267879A2 (en) | 2003-01-02 |
BG107157A (en) | 2003-06-30 |
LT5045B (lt) | 2003-08-25 |
PE20011179A1 (es) | 2001-12-06 |
KR20030011805A (ko) | 2003-02-11 |
CA2404687A1 (en) | 2001-10-11 |
ZA200207760B (en) | 2004-01-30 |
RU2239435C2 (ru) | 2004-11-10 |
CN1420774A (zh) | 2003-05-28 |
PL366089A1 (en) | 2005-01-24 |
GEP20043285B (en) | 2004-07-26 |
NZ522250A (en) | 2004-09-24 |
IL151475A0 (en) | 2003-04-10 |
NO20024645D0 (no) | 2002-09-27 |
US20020002147A1 (en) | 2002-01-03 |
AU2001249591A1 (en) | 2001-10-15 |
CZ20023003A3 (cs) | 2002-11-13 |
EE200200564A (et) | 2004-06-15 |
BR0109602A (pt) | 2004-06-29 |
NO20024645L (no) | 2002-09-27 |
SK12822002A3 (sk) | 2003-02-04 |
MXPA02009534A (es) | 2003-05-14 |
JP2003528905A (ja) | 2003-09-30 |
WO2001074329A2 (en) | 2001-10-11 |
CN1187052C (zh) | 2005-02-02 |
US7135465B2 (en) | 2006-11-14 |
LV12939B (en) | 2003-04-20 |
HUP0302631A2 (hu) | 2003-11-28 |
WO2001074329A3 (en) | 2002-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR027748A1 (es) | Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma | |
BRPI0409345A (pt) | sistema de liberação, pelìcula de sistema de liberação, e, processo para preparar o sistema de pelìcula de gel homogêneo | |
NO971965L (no) | Farmasöytisk preparat inneholdende en smeltbar bærer og fremgangsmåte for fremstilling derav | |
ES2159591T3 (es) | Composicion de liberacion controlada. | |
ES2118677T3 (es) | Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion. | |
ES2185758T3 (es) | Utilizacion de esteres grasos etoxilados como compuestos auto-emulsionables. | |
ES2123278T3 (es) | Procedimiento para producir un polimero superabsorbente mejorado. | |
BR0109575A (pt) | Formulação terapêutica, forma de dosagem oral, processo para a preparação de pelo menos uma pequena conta, e, pequena conta | |
CO5150202A1 (es) | Composicion de tisu facial y metodo para usarla para el secuestro de irritantes de la piel de la secrecion nasal | |
UA26455C2 (uk) | Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта | |
BR0210267A (pt) | Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases | |
AR002266A1 (es) | Composicion farmaceutica de gelatina blanda o forma de dosis que la incluye | |
BR9906372A (pt) | Composição farmaceutica aquosa para aplicação na mucosa | |
BR0116945A (pt) | Uma preparação para prevenção de restenose | |
ATE227136T1 (de) | Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon | |
CR6656A (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
BR0212975A (pt) | Elemento de liberação de dosagem controlada, e, métodos para a liberação de pelo menos um primeiro agente ativo para dentro do rúmen de um animal ruminante, para o tratamento, a profilaxia ou ambos de um estado infestado ou doentio em um animal ruminante e para a alteração do estado fisiológico de um animal ruminante | |
KR900701261A (ko) | 비만증 치료방법 | |
AR019622A1 (es) | Composicion dentifrica que contiene ingredientes reactivos encapsulados y un metodo para aplicar ajustes terapeuticos a los dientes utilizando dichacomposicion | |
ES2059495T3 (es) | Dispositivo de descarga de farmacos regulado por solubilidad. | |
GB1484972A (en) | Method of sterilising medical and surgical instruments | |
PE84399A1 (es) | Formas de dosificacion de sertralina de liberacion retardada | |
BRPI0510694A (pt) | composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole | |
BR0110150A (pt) | Método e composição para o tratamento de câncer por meio da administração de agentes quimioterápicos indutores da apoptose | |
ES2180729T3 (es) | Tratamiento terapeutico combinado de las patologias hiperproliferantes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |